Everyonemedicines
-100%
est. 2Y upside i
Rank
#4457
Sector
Biotechnology, Healthcare Technology Systems, Drug Discovery
Est. Liquidity
~0Y
Data Quality
Data: LowEveryONE Medicines has officially shut down as of March 7, 2026.
Last updated: March 10, 2026
EveryONE Medicines has shut down. Even in a theoretical 'bull' scenario where assets are liquidated, common equity holders are highly unlikely to receive any value after creditors and preferred shareholders are paid. The equity is worthless.
EveryONE Medicines has ceased operations. The base case is a complete loss for all common equity, as the company is undergoing liquidation and there is no ongoing business or future revenue stream.
The company has officially shut down as of March 7, 2026. This results in a complete loss of all equity value for common stock holders, as there is no business to continue, and assets will be used to satisfy creditors and preferred shareholders first.
Preference Stack Risk
severeAs a seed-stage company that has shut down, any capital raised by investors with preferred shares would be prioritized in liquidation, leaving no value for common stock holders.
Dilution Risk
highWhile dilution is no longer a forward-looking risk for a defunct company, the need for future funding rounds would have posed a high dilution risk had the company continued operations.
Secondary Liquidity
noneThere is no secondary market for equity in a company that has ceased operations.
Questions to Ask at the Interview
Strategic questions based on Everyonemedicines's data — designed to show you've done your homework.
- 1
“Given the shutdown of EveryONE Medicines, what were the primary challenges that led to the company's closure, particularly concerning the regulatory pathway and commercial viability of individualized ASO therapies?”
- 2
“What lessons can be learned from EveryONE Medicines' attempt to industrialize individualized medicines, especially regarding the competitive landscape with established pharmaceutical and biotech incumbents?”
- 3
“In light of the company's closure, how would you assess the inherent risks and capital requirements for startups aiming to innovate in highly regulated and capital-intensive sectors like rare disease drug discovery?”
Community
Valuation Sentiment
Our model estimates -100% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.